Montesinos, P., Cheong, J.-W., Daver, N., Fathi, A. T., Levis, M. J., Luger, S., … Erba, H. P. (2024). Trial in Progress: The Phase 3, Randomized, Double-Blind, Placebo-Controlled QuANTUM-Wild Study of Quizartinib in Combination With Chemotherapy and as Single-Agent Maintenance in Newly Diagnosed, FLT3-ITD-Negative Acute Myeloid Leukemia. In Blood (Vol. 144, pp. 1504.3-1504.3). American Society of Hematology. https://doi.org/10.1182/blood-2024-205101

Montesinos, Pau, June-Won Cheong, Naval Daver, Amir T. Fathi, Mark J. Levis, Selina Luger, Toshihiro Miyamoto, et al. “Trial in Progress: The Phase 3, Randomized, Double-Blind, Placebo-Controlled QuANTUM-Wild Study of Quizartinib in Combination With Chemotherapy and as Single-Agent Maintenance in Newly Diagnosed, FLT3-ITD-Negative Acute Myeloid Leukemia.” In Blood, 144:1504.3-1504.3. American Society of Hematology, 2024. https://doi.org/10.1182/blood-2024-205101.

Montesinos P, Cheong J-W, Daver N, Fathi AT, Levis MJ, Luger S, et al. Trial in Progress: The Phase 3, Randomized, Double-Blind, Placebo-Controlled QuANTUM-Wild Study of Quizartinib in Combination With Chemotherapy and as Single-Agent Maintenance in Newly Diagnosed, FLT3-ITD-Negative Acute Myeloid Leukemia. In: Blood. American Society of Hematology; 2024. p. 1504.3-1504.3.

Montesinos, Pau, et al. “Trial in Progress: The Phase 3, Randomized, Double-Blind, Placebo-Controlled QuANTUM-Wild Study of Quizartinib in Combination With Chemotherapy and as Single-Agent Maintenance in Newly Diagnosed, FLT3-ITD-Negative Acute Myeloid Leukemia.” Blood, vol. 144, no. Supplement 1, American Society of Hematology, 2024, pp. 1504.3-1504.3. Crossref, doi:10.1182/blood-2024-205101.

Montesinos P, Cheong J-W, Daver N, Fathi AT, Levis MJ, Luger S, Miyamoto T, Oliva EN, Perl AE, Récher C, Schlenk RF, Wang J, Zeidan AM, Liu L, Duong Y, Imadalou K, Alexis K, Nahar A, Burns K, Erba HP. Trial in Progress: The Phase 3, Randomized, Double-Blind, Placebo-Controlled QuANTUM-Wild Study of Quizartinib in Combination With Chemotherapy and as Single-Agent Maintenance in Newly Diagnosed, FLT3-ITD-Negative Acute Myeloid Leukemia. Blood. American Society of Hematology; 2024. p. 1504.3-1504.3.